Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region [J]. Lancet, 2002,359(9321): 1909-1915.
[4]
Reiman JM, Kmieciak M, Manjili MH, et al. Tumor immunoediting and immunosculpting pathways to cancer progression [J]. Semin Cancer Biol, 2007, 17(4): 275-287.
[5]
Takeda K, Hayakawa Y, et al. Involvement of tumor necrosis factor-related apoptosis -inducing ligand in surveillance of tumor metastasis by liver natural killer cells [J]. Nat Med,2001,7: 94-100.
[6]
Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo [J]. Nat Med,1999,5(2):157-163.
Riccioni R, Pasquini L, Mariani G, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL [J]. Haematologica, 2005, 90: 612-624.
[9]
Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL--on a path to cancer immunotherapy [J]. Immunity, 2003, 18: 1-6.
[10]
Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice[J]. J Immunol, 2002, 168: 1356-1361.
[11]
Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development [J]. J Exp Med,2002, 195: 161-169.
[12]
Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity[J]. Nat Med, 2002(8): 1433-1437.
[13]
Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosinekinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy [J]. Blood,2004, 103: 1085-1088.
[14]
Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras [J]. Blood, 2003,103: 767-776.
[15]
Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL [J].Science, 1997,276: 111-113.
[16]
Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and death domain-containing receptor for TRAIL [J]. Science, 1997, 277:815-821.
